Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

RELMADA THERAPEUTICS, INC.

RLMD · Nasdaq · CIK 0001553643 · Healthcare · Biotechnology

INSIDER SIGNAL

61.6 / 100

2 buyers · 4 purchase transaction lines · $1.7M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyModerate
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+19.3 / 25
Role+13.0 / 20
Recency+5.3 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Shenouda MagedChief Financial Officer
●●
TRAVERSA SERGIOChief Executive Officer
●●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION50%Largest buyer: Shenouda Maged · $844.0K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-09-09–2026-09-10

Roles in the peak window: Chief Executive Officer, Chief Financial Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

61.6 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 62.1
  2. 62.0
  3. 62.0
  4. 61.8
  5. 61.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

10Purchases
0Sales
0Other Form 4 lines
8SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-16.7%
3M
-47.4%
6M
-53.5%
12M
+59.2%

Volatility & liquidity

Volatility
139.7%
Beta
—
Avg daily value
USD 4.5M

Valuation

Market cap
USD 361.6M
P/E
—

Fundamentals

Profit margin
—
ROE
0.0%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-04 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
13,424,126
Previous report
14,463,677
Avg daily volume
1,033,660
Days to cover
13.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-10TRAVERSA SERGIOPurchase (P)Common Stock100,000USD 4.10USD 410,000SEC filing ↗
2026-09-10Shenouda MagedPurchase (P)Common Stock79,800USD 4.25USD 339,150SEC filing ↗
2026-09-09TRAVERSA SERGIOPurchase (P)Common Stock100,000USD 4.18USD 418,000SEC filing ↗
2026-09-09Shenouda MagedPurchase (P)Common Stock120,200USD 4.20USD 504,840SEC filing ↗
2025-12-15TRAVERSA SERGIOPurchase (P)Common Stock27,500USD 4.12USD 113,300SEC filing ↗
2025-12-15Shenouda MagedPurchase (P)Common Stock11,665USD 4.12USD 48,060SEC filing ↗
2025-11-05TRAVERSA SERGIOPurchase (P)Common Stock272,500USD 2.20USD 599,500SEC filing ↗
2025-11-05Shenouda MagedPurchase (P)Common Stock500,000USD 2.20USD 1,100,000SEC filing ↗
2025-11-05Kelly Paul EdwardPurchase (P)Common Stock90,000USD 2.20USD 198,000SEC filing ↗
2025-11-05Ence ChuckPurchase (P)Common Stock136,000USD 2.20USD 299,200SEC filing ↗
2025-08-28TRAVERSA SERGIOPurchase (P)Common Stock55,976USD 0.74USD 41,422SEC filing ↗
2025-08-27TRAVERSA SERGIOPurchase (P)Common Stock129,455USD 0.67USD 86,735SEC filing ↗
2025-08-26TRAVERSA SERGIOPurchase (P)Common Stock80,545USD 0.62USD 49,938SEC filing ↗
2025-05-20TRAVERSA SERGIOPurchase (P)Common Stock147,686USD 0.56USD 82,704SEC filing ↗
2025-05-20Shenouda MagedPurchase (P)Common Stock60,000USD 0.52USD 31,200SEC filing ↗

Form 4 evidence

10 transaction lines in the latest 365-day window; 164 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-10TRAVERSA SERGIOPurchase (P)Common Stock100,000USD 4.10USD 410,000SEC filing ↗
2026-09-10Shenouda MagedPurchase (P)Common Stock79,800USD 4.25USD 339,150SEC filing ↗
2026-09-09TRAVERSA SERGIOPurchase (P)Common Stock100,000USD 4.18USD 418,000SEC filing ↗
Show recent Form 4 evidence (10 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-10TRAVERSA SERGIOPurchase (P)Common Stock100,000USD 4.10USD 410,000SEC filing ↗
2026-09-10Shenouda MagedPurchase (P)Common Stock79,800USD 4.25USD 339,150SEC filing ↗
2026-09-09TRAVERSA SERGIOPurchase (P)Common Stock100,000USD 4.18USD 418,000SEC filing ↗
2026-09-09Shenouda MagedPurchase (P)Common Stock120,200USD 4.20USD 504,840SEC filing ↗
2025-12-15TRAVERSA SERGIOPurchase (P)Common Stock27,500USD 4.12USD 113,300SEC filing ↗
2025-12-15Shenouda MagedPurchase (P)Common Stock11,665USD 4.12USD 48,060SEC filing ↗
2025-11-05TRAVERSA SERGIOPurchase (P)Common Stock272,500USD 2.20USD 599,500SEC filing ↗
2025-11-05Shenouda MagedPurchase (P)Common Stock500,000USD 2.20USD 1,100,000SEC filing ↗
2025-11-05Kelly Paul EdwardPurchase (P)Common Stock90,000USD 2.20USD 198,000SEC filing ↗
2025-11-05Ence ChuckPurchase (P)Common Stock136,000USD 2.20USD 299,200SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerRLMD
CIK0001553643
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history164 transaction lines from 2020-03-17 to 2026-09-10
40 P purchase lines · 81 S sale lines · 43 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.